16 clinical trials found.
-
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ... -
A Phase 3 Randomized Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1 and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study of pembrolizumab + lenvatinib in cisplatin-ineligible participants whose tumors express PD-L1 (CPS =10), and in participants ineligible ... -
A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)
This is a research study involving the drug pembrolizumab. The purpose of this study is to: o See if pembrolizumab before and after surgery is ... -
A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TRQ15-01 administered i.v. in patients with relapsed ... -
A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
If you have been diagnosed with BCG unresponsive, high-risk, non-muscle invasive bladder cancer, you may qualify for this study. The main purpose of the study ... -
Afatinib in advanced refractory urothelial cancer
If you have been diagnosed with urothelial cancer (a type of bladder cancer), which cannot be removed surgically at this time and has grown after ... -
A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal ... -
PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION
The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of your ... -
A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
If you have been diagnosed with locally advanced or metastatic (the spread of) melanoma, locally advanced or metastatic (the spread of) urothelial bladder cancer or ... -
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase ...
